Jang, J., Han, Y., Lee, H., Kim, S., Kwon, W., Lee, K., . . . Choi, S. H. (2018). Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer; A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Annals of Surgery, 268(2), 215-222. https://doi.org/10.1097/SLA.0000000000002705

Jang, Jin-Young, Youngmin Han, Hongeun Lee, Sun-Whe Kim, Wooil Kwon, Kyung-Hun Lee, Do-Youn Oh, Eui Kyu Chie, and Seong Ho Choi. "Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer; A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial." Annals of Surgery 268, no. 2 (2018): 215-222. https://doi.org/10.1097/SLA.0000000000002705.

Jang, Jin-Young, et al. "Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer; A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial." Annals of Surgery, vol. 268, no. 2, 2018, pp. 215-222, https://doi.org/10.1097/SLA.0000000000002705.